semaglutide life extension Ozempic Pill Flops in Major Trials for Alzheimer's Semaglutide from Bench to Bedside:

Oral semaglutide is, paradoxically, often the least convenient despite being a pill, because of its rigid daily dosing protocol

Lopes Andrade AW, Dias Ribeiro Figueiredo D, Torequl Islam M, Viana Nunes AM, da, Conceio Machado K

Final Verdict: 7 Clinical Facts Ozempic is not licensed for weight loss in the UK Wegovy is the licensed semaglutide weight management product Mounjaro and Wegovy are different drugs tirzepatide (dual GLP-1/GIP) vs semaglutide (GLP-1 only) In the SURMOUNT-5 head-to-head trial, Mounjaro produced 20.2% vs Wegovys 13.7% average weight loss Wegovy is approximately 75/month cheaper at Slinic maintenance doses important for cost-sensitive patients Wegovy has the NICE cardiovascular indication (April 2026) Mounjaro does not yet have this label Wegovy now has a licensed oral version (MHRA June 2026) Mounjaro does not yet have an oral equivalent Neither Ozempic off-label nor compounded alternatives are appropriate when licensed products are readily available from a GPhC-registered UK pharmacy Slinic prescribes Mounjaro and Wegovy both correctly licensed, both from Eli Lilly and Novo Nordisk authorised supply chains, both reviewed by a registered UK prescriber

Cagrilintide adds a powerful new tool to the arsenal, especially when strategically combined with other therapies

These tiny, malleable bacteria lack a rigid cell wall and are notoriously difficult to